These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 26695682)

  • 1. Clinical Trial Risk in Chronic Obstructive Pulmonary Disease: The Effects of Drug Class and Inclusion Criteria.
    Tam JT; Parker JL; Anastasopulos D; Balter MS
    Respiration; 2016; 91(1):79-86. PubMed ID: 26695682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD.
    Hanania NA
    Pulm Pharmacol Ther; 2008; 21(3):540-50. PubMed ID: 18280761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Cardiovascular Events Associated with Inhaled Corticosteroid Treatment in Patients with Chronic Obstructive Pulmonary Disease: A Meta-Analysis.
    Jing X; Li Y; Xu J
    Can Respir J; 2018; 2018():7097540. PubMed ID: 30123392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in COPD disease management with fixed-dose long-acting combination therapies.
    Bateman ED; Mahler DA; Vogelmeier CF; Wedzicha JA; Patalano F; Banerji D
    Expert Rev Respir Med; 2014 Jun; 8(3):357-79. PubMed ID: 24802656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease--The Shifting Treatment Paradigm.
    Wilkie M; Finch S; Schembri S
    COPD; 2015; 12(5):582-90. PubMed ID: 25774769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of inhaled corticosteroids in monotherapy or combined with long-acting {beta}2-agonists on mortality among patients with chronic obstructive pulmonary disease.
    Cyr MC; Beauchesne MF; Lemière C; Aaron SD; Blais L
    Ann Pharmacother; 2010 Apr; 44(4):613-22. PubMed ID: 20233915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of long acting β₂-agonists, alone or in combination with inhaled corticosteroids, in chronic obstructive pulmonary disease (COPD): a risk-benefit analysis.
    Cave AC; Hurst MM
    Pharmacol Ther; 2011 May; 130(2):114-43. PubMed ID: 21276815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-persistence and non-adherence to long-acting COPD medication therapy: A retrospective cohort study based on a large German claims dataset.
    Mueller S; Wilke T; Bechtel B; Punekar YS; Mitzner K; Virchow JC
    Respir Med; 2017 Jan; 122():1-11. PubMed ID: 27993284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COPD exacerbation frequency, pharmacotherapy and resource use: an observational study in UK primary care.
    Thomas M; Radwan A; Stonham C; Marshall S
    COPD; 2014 Jun; 11(3):300-9. PubMed ID: 24152210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introduction to the Canadian Scientific Advisory Committee on Respiratory and Allergy Therapies: in vivo evaluation for clinical testing in COPD and asthma therapy using generics.
    Mayers I
    J Aerosol Med Pulm Drug Deliv; 2012 Aug; 25(4):204-8. PubMed ID: 22007673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory pharmacotherapy use in patients newly diagnosed with chronic obstructive pulmonary disease in a primary care setting in the UK: a retrospective cohort study.
    Wurst KE; Shukla A; Muellerova H; Davis KJ
    COPD; 2014 Sep; 11(5):521-30. PubMed ID: 24945236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival of COPD patients using inhaled corticosteroids and long-acting beta agonists.
    Mapel DW; Hurley JS; Roblin D; Roberts M; Davis KJ; Schreiner R; Frost FJ
    Respir Med; 2006 Apr; 100(4):595-609. PubMed ID: 16199151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organization.
    Gagnon YM; Levy AR; Spencer MD; Hurley JS; Frost FJ; Mapel DW; Briggs AH
    Respir Med; 2005 Dec; 99(12):1534-45. PubMed ID: 16291076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhaled Pharmacotherapy and Stroke Risk in Patients with Chronic Obstructive Pulmonary Disease: A Nationwide Population Based Study Using Two-Stage Approach.
    Lin HW; Chung CL; Lin YS; Yu CM; Lee CN; Bien MY
    PLoS One; 2015; 10(7):e0130102. PubMed ID: 26158649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Cardiovascular and Cerebrovascular Safety of Inhaled Long-Acting Bronchodilators in Patients with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study.
    Dong YH; Chang CH; Gagne JJ; Hsu CL; Lai MS
    Pharmacotherapy; 2016 Jan; 36(1):26-37. PubMed ID: 26799347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Friend or foe: combination therapy with inhaled corticosteroids and long-acting beta2-agonists in chronic obstructive pulmonary disease (COPD)].
    Gillissen A; Gessner C; Hoheisel G; Juergens U
    Pneumologie; 2008 Jul; 62(7):430-7. PubMed ID: 18398787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD.
    Ohar JA; Donohue JF
    Semin Respir Crit Care Med; 2010 Jun; 31(3):321-33. PubMed ID: 20496301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhaled corticosteroids and risk of lung cancer among COPD patients who quit smoking.
    Kiri VA; Fabbri LM; Davis KJ; Soriano JB
    Respir Med; 2009 Jan; 103(1):85-90. PubMed ID: 18793832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease.
    Joos GF
    Expert Opin Investig Drugs; 2010 Feb; 19(2):257-64. PubMed ID: 20047505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pneumology. Inhaled corticosteroids in COPD: more and interesting data!].
    Rochat T
    Rev Med Suisse; 2008 Jan; 4(140):155-7. PubMed ID: 18309880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.